Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot slashes hidden heart risk in phase 2 trial

NCT ID NCT04270760

Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested olpasiran, an injectable drug, in 281 adults with high lipoprotein(a) – a genetic risk factor for heart disease. Participants received either olpasiran or a placebo. The main goal was to see how much the drug lowered Lp(a) levels after 36 weeks. Results showed a significant reduction, suggesting olpasiran may help control this stubborn risk factor.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Olpasiran (AMG 890)
What this could lead to
If successful, olpasiran could become a new treatment to lower high lipoprotein(a), a genetic risk factor for heart disease and stroke.
What could go wrong
This is a phase 2 trial with 281 participants, so results are still early. It is not yet proven to reduce heart attacks or strokes, only to lower a lab marker.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

281 people

The number who actually took part.

Started

Jul 2020

Finished

Nov 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 80 years * Lipoprotein (a) \> 150 nmol/L * Evidence of atherosclerotic cardiovascular disease Exclusion Criteria: * Severe renal dysfunction * History or clinical evidence of hepatic dysfunction * Malignancy within the last 5 years * Currently receiving, or less than 3 months at Day 1 since receiving \> 200 mg/day Niacin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerotic cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease cardiovascular disorder Dyslipidemias hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease

Contacts and locations

Locations

  • Aarhus Universitetshospital

    Aarhus N, 8200, Denmark

  • Academisch Medisch Centrum

    Amsterdam, 1105 AZ, Netherlands

  • Asahi General Hospital

    Asahi-shi, Chiba, 289-2511, Japan

  • Asahikawa City Hospital

    Asahikawa-shi, Hokkaido, 070-8610, Japan

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Clinique des Maladies Lipidiques de Quebec Incorporated

    Québec, Quebec, G1V 4W2, Canada

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Core Research Group Pty Ltd

    Milton, Queensland, 4064, Australia

  • Crossroads Clinical Research Inc

    Mooresville, North Carolina, 28117, United States

  • Dr Heart Pty Ltd

    Woolloongabba, 4102, Australia

  • Ecogene-21

    Chicoutimi, Quebec, G7H 7K9, Canada

  • Excel Medical Clinical Trials

    Boca Raton, Florida, 33434, United States

  • Haga Ziekenhuis

    The Hague, 2545 AA, Netherlands

  • Herlev Gentofte Hospital

    Herlev, 2730, Denmark

  • Johns Hopkins

    Baltimore, Maryland, 21287, United States

  • Kanazawa Medical University Hospital

    Kahoku-gun, Ishikawa-ken, 920-0293, Japan

  • LMC Clinical Research Incorporated

    Brampton, Ontario, L6S 0C6, Canada

  • LMC Clinical Research Incorporated Thornhill

    Concord, Ontario, L4K 4M2, Canada

  • Linear Clinical Research Limited

    Nedlands, Western Australia, 6009, Australia

  • Monash Medical Centre

    Clayton, Victoria, 3168, Australia

  • Mount Sinai Hospital

    New York, New York, 10029, United States

  • New York University

    New York, New York, 10016, United States

  • Piedmont Healthcare

    Atlanta, Georgia, 30309, United States

  • Protenium Clinical Research

    Hurst, Texas, 76054, United States

  • Regionshospitalet Viborg

    Viborg, 8800, Denmark

  • Research Institute of McGill University Health Center - Glen Site

    Montreal, Quebec, H4A 3J1, Canada

  • Rijnstate Ziekenhuis

    Arnhem, 6815 AD, Netherlands

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, 2050, Australia

  • Saitama Medical University Hospital

    Iruma-gun, Saitama, 350-0495, Japan

  • The Jikei University Kashiwa Hospital

    Kashiwa-shi, Chiba, 277-8567, Japan

  • Thjonustumidstod Rannsoknaverkefna

    Kopavogur, 201, Iceland

  • Universitair Medisch Centrum Utrecht

    Utrecht, 3584 CX, Netherlands

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

  • VieCuri Medisch Centrum

    Venlo, 5912 BL, Netherlands

  • Westside Medical Associates of Los Angeles

    Beverly Hills, California, 90211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.